Monza, Italy

Ennio Cavalletti


Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 24(Granted Patents)


Location History:

  • Monza, IT (1996)
  • Milan, IT (1989 - 1997)

Company Filing History:


Years Active: 1989-1997

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ennio Cavalletti: Innovator in Chemoprotective Agents

Introduction

Ennio Cavalletti is a notable inventor based in Monza, Italy. He has made significant contributions to the field of chemoprotective agents, holding a total of 3 patents. His work focuses on developing novel compounds that can enhance the safety and efficacy of cancer treatments.

Latest Patents

One of Cavalletti's latest patents is centered around glutathione as a chemoprotective agent. He has also worked on the compound 6,9-bis[(2-aminoethyl) amino]benzo[g]isoquinoline-5,10-dione. In the search for novel heteroanalogs of anthracenediones, 6,9-bis[(2-aminoethyl-amino]-benzo[g]isoquinoline-5,10-dione dimaleate (BBR 2778) was selected as the most promising compound. Toxicological studies indicate that BBR 2778 is not cardiotoxic, showcasing its potential for safe application in medical treatments.

Career Highlights

Cavalletti has had a distinguished career, working with reputable companies such as Boehringer Mannheim Italia, S.p.a. and Boehringer Biochemia Robin S.p.a. His experience in these organizations has contributed to his expertise in the development of innovative pharmaceutical compounds.

Collaborations

Throughout his career, Cavalletti has collaborated with notable colleagues, including Sergio Tognella and Michele Tedeschi. These partnerships have fostered a collaborative environment that has led to significant advancements in their respective fields.

Conclusion

Ennio Cavalletti's work in the development of chemoprotective agents highlights his innovative spirit and dedication to improving cancer treatment safety. His contributions continue to influence the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…